Alissa Kamens
Strategic Collaborations Manager Promega Corporation
Seminars
Thursday 30th April 2026
Interrogating GPCR Biology Across the Signaling Cascade: NanoLuc-Based Tools for Drug Discovery
2:10 pm
- Deploying HiBiT/NanoBRET Target Engagement assays at endogenous receptor expression levels to quantify ligand binding and competitive displacement without the overexpression artifacts that confound pharmacological interpretation
- Resolving transient versus stable receptor–β-arrestin complexes in real time using NanoBiT complementation, enabling kinetic discrimination of Class A versus Class B GPCR trafficking behavior relevant to biased agonism studies
- Profiling internalization and arrestin recruitment of incretin receptors (GLP-1R, GIPR, GCGR) with semaglutide, tirzepatide, and retatrutide to demonstrate how a unified bioluminescent platform captures polypharmacology across next-generation GPCR-targeted therapeutics
- Integrating real-time and endpoint cAMP assays with broad dynamic range to link upstream receptor engagement to downstream G-protein signaling outputs in a single, scalable workflow compatible with HTS
